Press release from Companies
Published: 2025-05-15 16:09:23
Copenhagen, Denmark, 15 May 2025 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the disclosure of participation by members of Curasight’s Board of Directors, Executive Management and team members in the Right Issue 2025 by exercise Curasight TO subscription rights to purchase new shares in the period May 12 - May 14, 2025.
The following is an overview of the transactions relating to participation in the Right Issue 2025:
| Name | Position | Aggregated volume, new shares | Price, DKK |
| Kirsten Drejer | Chair of the Board | 45,000 | 89,100.00 |
| Lars Trolle | Deputy chair of the Board | 81,103 | 160,583.94 |
| Ulrich Krasilnikoff | CEO & CFO, Board member | 1,297,379 | 2,568,810.42 |
| Andreas Kjær | CMO & CSO, Board member | 1,262,626 | 2,499,999.48 |
| Jacob Madsen | Director CMC and co-founder | 26,220 | 51,915.60 |
| Total | 2,712,328 | 5,370,409.44 |
For further information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.
